ARMP
Armata Pharmaceuticals, Inc.
Next earnings Aug 10, 2026 · consensus $-0.42 EPS
Last earnings -2.0% on 2026-05-13
$7.40
▲ +13.85%$7.40▲ +283.42%
over 1Y
L $1.84EODHDH $14.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+13.8%
1W+7.7%
1M-7.2%
3M-11.6%
YTD+12.8%
1Y+283.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity -1.35x).
Armata Pharmaceuticals, Inc. shows limited reported revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.8M | -$36.9M | -$40.9M | -$42.4M | -$36.6M |
| Net income | -$23.2M | -$36.9M | -$69.0M | -$18.9M | -$174M |
| Diluted EPS | -$0.96 | -$1.08 | -$1.91 | -$0.89 | -$4.80 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$262M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-64.1%
FCF yield-9.7%
Quality & risk
ROIC (est.)—
Free cash flow-$26.3M
Total debt—
Net cash$8.69M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+1.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-K/APeriod ending 2026-04-242026-06-24open ↗8-KPeriod ending 2026-06-232026-06-23open ↗8-KPeriod ending 2026-06-112026-06-16open ↗SCHEDULE 13D/AFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-122026-05-13open ↗8-KPeriod ending 2026-05-072026-05-07open ↗4Period ending 2026-04-242026-04-28open ↗3Period ending 2026-04-242026-04-28open ↗ARSPeriod ending 2025-12-312026-04-27open ↗DEF 14APeriod ending 2026-06-112026-04-27open ↗8-KPeriod ending 2026-04-242026-04-27open ↗
Frequently asked
- Is Armata Pharmaceuticals, Inc. (ARMP) a buy?
- ARMP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.35x).
- What is Armata Pharmaceuticals, Inc.'s quality score?
- ARMP scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000921114, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:47:50 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.